Literature DB >> 18422519

Diazepam versus fentanyl for premedication during percutaneous coronary intervention: results from the Myocardial Protection by Fentanyl during Coronary Intervention (PROFIT) Trial.

Mohamed Abdel-Wahab1, Ahmed A Khattab, Branislav Liska, Guido Kassner, Volker Geist, Ralph Toelg, Gert Richardt.   

Abstract

BACKGROUND: Sedation is a cornerstone in the premedication for percutaneous coronary intervention (PCI). Benzodiazepines and opioids are frequently used. Previous results suggest that opioids mimic the adaptation to ischemia during repeated balloon inflations and may provide direct myocardial protection in addition to their sedative effect. However, no comparative data exist.
METHODS: We conducted a prospective, randomized, controlled, single-blind trial comparing diazepam and fentanyl in 276 patients undergoing elective PCI. Patients were randomized to either diazepam 5 mg sublingually or fentanyl 0.05 mg or 0.1 mg intravenously at least 5 minutes prior to the first balloon inflation. The primary end-point was the postprocedural elevation of myocardial markers of necrosis defined as an elevation of cardiac troponin T > or = 0.01 ng/ml.
RESULTS: The three groups had similar baseline clinical, angiographic, and procedural characteristics, with no significant differences in lesion morphology, procedural complexity, or adjunctive medical treatment. No significant variation in the hemodynamic response to the study drugs was observed in the three groups. The rate of postprocedural troponin T elevation was 28% in the diazepam group, 20% in the fentanyl 0.05 mg group, and 30% in the fentanyl 0.1 mg group (P = 0.26). Rates of postprocedural myocardial infarction were 3%, 2%, and 2%, respectively (P = 0.84), with one case of in-hospital death in the diazepam group and no urgent TVR in the whole study population.
CONCLUSION: Although providing a well-tolerated alternative to diazepam for sedation during PCI, fentanyl did not provide additional cardioprotection assessed through the postinterventional elevation of cardiac troponin T during elective coronary intervention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18422519     DOI: 10.1111/j.1540-8183.2008.00355.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  4 in total

Review 1.  Opioid-induced cardioprotection.

Authors:  Katsuya Tanaka; Judy R Kersten; Matthias L Riess
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 2.  Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.

Authors:  John P Headrick; Louise E See Hoe; Eugene F Du Toit; Jason N Peart
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

Review 3.  Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection?

Authors:  P Kleinbongard; G Heusch
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

4.  Effect and Safety of Morphine Use in Acute Anterior ST-Segment Elevation Myocardial Infarction.

Authors:  Mickael Bonin; Nathan Mewton; Francois Roubille; Olivier Morel; Guillaume Cayla; Denis Angoulvant; Meyer Elbaz; Marc J Claeys; David Garcia-Dorado; Céline Giraud; Gilles Rioufol; Claire Jossan; Michel Ovize; Patrice Guerin
Journal:  J Am Heart Assoc       Date:  2018-02-10       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.